|
|
 |
M. D. Anderson conducts one of the world's largest clinical trials programs, offering more than 1,000 clinical trials – the most available anywhere – including treatment, prevention, diagnosis, survivorship and quality of life. Many of these studies are only offered here.
Find out if your patients are eligible / collaborate on research. In the Office of Physician Relations, we help identify the appropriate research staff to discuss clinical trials and eligibility criteria specific for your patient. |
|
| |
Contact Our Office for Assistance
- FAX the completed Clinical Trial Information Request Form to (713) 794-4685
- Phone our office for assistance at (713) 792-6161 or (800) 392-1611
- E-mail us at physicianrelations@mdanderson.org
We will contact you within 48 hours (excluding weekends and holidays) with the status of your request.
Download a Clinical Trials Request Form
|
View Studies By:
Cancer Type | Treatment | Study Number | Physician | Phase | Clinical Trials Registration Number (NCT#)
About Clinical Trials
What Are They? | The Phases of Clinical Trials | Participating in Clinical Trials | Frequently Asked Questions
Featured Clinical Trial for Sarcoma
Protocol NCT00785785: A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST)
The purpose of this clinical research study is to compare the safety and effectiveness of Tasigna (nilotnib) to Gleevec (imatinib mesylate) in patienst with a GIST.
To refer a patient or discuss this study in more detail, please contact Rosnie Adinin R.N. at 713-563-0004. The lead investigator for this study is Dr. Jonathan Trent.
New Standard Treatment Shows Benefits for Rare Pediatric Brain Cancer
A team of researchers led by M. D. Anderson recently revealed results from the largest-ever collaborative study addressing the treatment of a rare pediatric brain tumor. The findings suggest a new standard protocol could improve survival nearly two-fold for pediatric patients with choroid plexus tumors, as reported at the 41st Annual Meeting of the International Society of Pediatric Oncology.
Johannes Wolff, M.D., professor, Pediatrics and lead investigator on the study, revealed that the protocol, consisting of three chemotherapy agents and radiation, had projected overall survival rates of 93% at one year, 82% at five years, and 78% at eight years.
"This SIOP 2000 study started 10 years ago and has grown to include more than 100 institutions from more than 20 countries," Wolff says. "With the data we have, we can tell which patients are prone to do better and which ones have a poor prognosis. In addition, we've established a promising standard protocol for these patients."
Choroid plexus carcinomas are malignant brain tumors affect approximately 1,500 children worldwide each year, occurring more often in infants.
Due to the rarity of the disease, there is no standard treatment protocol for the disease, but Wolff and other international researchers hope to change that through their studies. They also developed an innovative statistical module for institutions to use that will ensure quality and efficient data coming out of the study.
For the full news release, visit the M. D. Anderson Newsroom.
Featured Clinical Trials for Relapsed/Refractory Hodgkins' Lymphoma
Protocol # 2008-0401: Phase II study of oral Panobinostat in adult patients with relapsed/refractory classical Hodgkins' lymphoma after failure of high-dose chemotherapy with autologous stem cell transfusion and a Gemcitabine or Vinorelbine containing treatment regimen.
The purpose of this study is to evaluate the effect of panobinostat, given by mouth, to patients with relapsed/refractory Hodgkins' lymphoma.
To refer a patient to this clinical trial, contact Dr. Anas Younes at 713-745-4256, or the study research nurse Amanda Copeland at 713-792-9455.
Protocol # 2008-0639: Phase II study of SGN-35 in treatment of patients with relapsed or refractory Hodgkins' lymphoma.
The purpose of this pivotal study is to assess the efficacy of SGN-35 in patients with relapsed/refractory Hodgkins' lymphoma.
To refer a patient to this clinical trial, contact Dr. Anas Younes at 713-745-4256, or the study research nurse Amanda Copeland at 713-792-9455.
|
|
